WHO Adds First Ebola Bundibugyo Diagnostic Test to Emergency Use Listing Amid DRC Outbreak

The speed at which WHO's Emergency Use Listing mechanism moved from outbreak declaration to listed diagnostic product signals what accelerated regulatory pathways can achieve under pressure — and sets a reference point for IVD manufacturers navigating expedited submissions. Less than seven weeks elapsed between the 17 May 2026 declaration of a public health emergency of international concern over Ebola Bundibugyo virus (BDBV) and the listing of the first molecular diagnostic test for the pathogen.

The listed test detects BDBV by identifying viral genetic material in blood samples. WHO's EUL procedure evaluated the product against minimum international standards for quality, safety, and performance, with explicit consideration of the needs of low- and middle-income countries — the primary deployment context. The listing enables UN procurement agencies and national governments to move forward on procurement decisions with a WHO quality assurance reference in hand.

The outbreak context underlines why turnaround speed mattered. As of 2 July 2026, the Democratic Republic of the Congo had recorded 1,406 laboratory-confirmed cases and 438 deaths from the largest documented BDBV outbreak. Testing infrastructure has scaled in parallel: laboratory capacity expanded from an estimated 200–400 tests per day at two Institut National de Recherche Biomédicale sites to more than 2,000 tests per day across a ten-laboratory network spanning affected provinces, supported by WHO and Africa CDC.

For regulatory affairs leads tracking expedited pathways, the BDBV EUL sequence is instructive. WHO issued a call for Expressions of Interest from IVD manufacturers within two weeks of the PHEIC declaration — compressing a process that typically unfolds over months. Additional BDBV IVD applications remain under review, and WHO, Africa CDC, PATH, FIND, and CHAI, with Unitaid support, are standing up a joint validation platform to generate clinical performance evidence on laboratory-based molecular tests, near-point-of-care molecular tests, and antigen rapid diagnostic tests in outbreak settings.

The validation platform is designed to produce the kind of real-world performance data that regulators and procurement bodies require before scaling deployment — a step that IVD manufacturers with products in the pipeline should track closely as the evidence base develops.

Source: World Health Organization via WHO News (English), 2 July 2026.